Key points are not available for this paper at this time.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). However, given that MASLD requires at least one cardiometabolic risk factor, questions were raised as to whether new evidence would need to be generated for MASLD. In this issue, Younossi and coworkers compared the clinical profile and outcomes of NAFLD to MASLD using a tertiary-care NAFLD database and NHANES-III. Ninety-nine percent of included patients met MASLD criteria while 95% met MASLD criteria on BMI only.
Burra et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: